Back
Tarsus Pharmaceuticals Quote, Financials, Valuation and Earnings
The Next Tech Giant in Your Pocket?
This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Buy
68
TARS
Tarsus Pharmaceuticals
Last Price:
31.96
Seasonality Move:
3.41%
7 Day Trial
ALL ACCESS PASS
$
7
Hope Is Not a Strategy!
Learn MoreTarsus Pharmaceuticals Price Quote
$31.96
-1.30 (-3.91%)
(Updated: September 16, 2024 at 4:00 PM ET)
Tarsus Pharmaceuticals Key Stats
Buy
68
Tarsus Pharmaceuticals (TARS)
is a Buy
Day range:
$31.50 - $33.39
52-week range:
$12.57 - $42.50
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
13.67
P/B ratio:
5.02%
Volume:
641.4K
Avg. volume:
819.3K
1-year change:
121.88%
Market cap:
$1.3B
Revenue:
$17.4M
EPS:
$-4.48
How Much Does Tarsus Pharmaceuticals Make?
-
How Much Are Tarsus Pharmaceuticals's Sales Annually?
TARS Revenues are $17.4M -
How Much Profit Does Tarsus Pharmaceuticals's Make A Year?
TARS net income is -$135.9M
Is Tarsus Pharmaceuticals Growing As A Company?
Data Unavailable
Tarsus Pharmaceuticals Stock Price Performance
-
Did Tarsus Pharmaceuticals Stock Go Up Last Month?
Tarsus Pharmaceuticals share price went up by 25.79% last month -
Did TARS's Share Price Rise Over The Last Year?
TARS share price rose by 121.88% over the past 1 year
What Is Tarsus Pharmaceuticals 52-Week High & Low?
-
What Is Tarsus Pharmaceuticals’s 52-Week High Share Price?
Tarsus Pharmaceuticals has traded as high as $42.50 over the past 52 weeks -
What Is Tarsus Pharmaceuticals’s 52-Week Low Share Price?
Tarsus Pharmaceuticals has traded as low as $12.57 over the past 52 weeks
Tarsus Pharmaceuticals Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Tarsus Pharmaceuticals?
-
How Much Debt Does Tarsus Pharmaceuticals Have?
Total long term debt quarterly is $71.6M -
How Much Cash Does Tarsus Pharmaceuticals Have?
Cash and short term investments quarterly total is $323.6M -
What Is Tarsus Pharmaceuticals’s Book Value Per Share?
Book value per share is 6.63
Is Tarsus Pharmaceuticals Cash Flow Positive?
-
What Is TARS Cash Flow From Operations?
Cash flow from operations (TTM) is -$123.9M -
What Is Tarsus Pharmaceuticals’s Cash Flow From Financing?
Cash flow from financing (TTM) is $275.7M -
What Is Tarsus Pharmaceuticals’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$77.5M
Tarsus Pharmaceuticals Return On Invested Capital
-
Is Management Doing A Good Job?
TARS return on invested capital is -59.01% -
What Is Tarsus Pharmaceuticals Return On Assets?
ROA measures how assets are converting to revenues and is -51.79% -
What Is TARS Return On Equity?
ROE is a measure of profitability and is -69.1%
Tarsus Pharmaceuticals Earnings Date & Stock Price
-
What Is Tarsus Pharmaceuticals's Stock Price Today?
A single share of TARS can be purchased today for 33.26 -
What Is Tarsus Pharmaceuticals’s Stock Symbol?
Tarsus Pharmaceuticals trades on the nasdaq under the ticker symbol: TARS -
When Is Tarsus Pharmaceuticals’s Next Earnings Date?
The next quarterly earnings date for Tarsus Pharmaceuticals is scheduled on November 8, 2024 -
When Is TARS's next ex-dividend date?
Tarsus Pharmaceuticals's next ex-dividend date is September 16, 2024 -
How To Buy Tarsus Pharmaceuticals Stock?
You can buy Tarsus Pharmaceuticals shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Tarsus Pharmaceuticals Competitors
-
Who Are Tarsus Pharmaceuticals's Competitors?
Below is a list of companies who compete with Tarsus Pharmaceuticals or are related in some way:
Tarsus Pharmaceuticals Dividend Yield
-
What Is TARS Dividend Yield?
Tarsus Pharmaceuticals’s dividend yield currently is 0% -
What Is Tarsus Pharmaceuticals’s Payout Ratio?
Tarsus Pharmaceuticals’s payout ratio is 0% -
When Did Tarsus Pharmaceuticals Last Pay A Dividend?
The latest dividend pay date is September 16, 2024 -
What Is Tarsus Pharmaceuticals’s Dividend Per Share?
Tarsus Pharmaceuticals pays a dividend of $0.00 per share
Tarsus Pharmaceuticals Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | 0% | -3.8% |
| Revenue: | 0% | 27.35% |
Analyst Recommendations
| Buy Recommendations: | 6 |
|---|---|
| Hold Recommendations: | 1 |
| Sell Recommendations: | 0 |
| Price Target: | 59.22 |
| Upside from Last Price: | 78.06% |